Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Emond

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Advances in Therapy|November 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Oncology and Therapy|April 18, 2026
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US DatabasesSurbhi Sidana, Saurabh P Nagar, Sabyasachi Ghosh, et al.
Leukemia & Lymphoma|October 1, 2024
Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphomaMazyar Shadman, Monika Salkar, Bhavini Srivastava, et al.
Clinical Epidemiology|June 2, 2026
Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple MyelomaDoris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.
Advances in Therapy|March 24, 2026
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USASikander Ailawadhi, Doris K Hansen, Binod Dhakal, et al.
Current Medical Research and Opinion|April 30, 2026
Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptomsDoris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 19, 2016
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infectionRobert J Fontana, Robert S Brown, Ana Moreno-Zamora, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Advances in Therapy|November 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Oncology and Therapy|April 18, 2026
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US DatabasesSurbhi Sidana, Saurabh P Nagar, Sabyasachi Ghosh, et al.
Leukemia & Lymphoma|October 1, 2024
Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphomaMazyar Shadman, Monika Salkar, Bhavini Srivastava, et al.
Clinical Epidemiology|June 2, 2026
Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple MyelomaDoris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.
Advances in Therapy|March 24, 2026
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USASikander Ailawadhi, Doris K Hansen, Binod Dhakal, et al.
Current Medical Research and Opinion|April 30, 2026
Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptomsDoris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 19, 2016
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infectionRobert J Fontana, Robert S Brown, Ana Moreno-Zamora, et al.
Pageof 8